The Annals of Oncology, the journal leader in neoadjuvant immunotherapy, showed an increasing trend in the percentage of annual citations (Fig. 2 K), whereas Nature, the journal leader in adjuvant immunotherapy, showed a decreasing trend in the percentage of annual citations (Fig. 2 L).
← all excerpts
Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: a global-scale, cross-sectional, and large-sample informatics study.
2
—
—
The sentences
The top 10 cited classics in neoadjuvant immunotherapy demonstrated an annual increasing trend in citations, whereas those in adjuvant immunotherapy showed a decreasing trend.